Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H11NO3S |
| Molecular Weight | 201.243 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(=O)N1[C@@H](C(O)=O)C(C)(C)S2
InChI
InChIKey=RBKMMJSQKNKNEV-RITPCOANSA-N
InChI=1S/C8H11NO3S/c1-8(2)6(7(11)12)9-4(10)3-5(9)13-8/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. | 2001 |
|
| Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. | 2001 |
|
| Rahnella aquatilis bacteremia in a patient with relapsed acute lymphoblastic leukemia. | 2001 |
|
| An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone. | 2001 Aug |
|
| Renal abscess: recovery without hospitalization and drainage. | 2001 Aug |
|
| Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. | 2001 Aug |
|
| Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. | 2001 Dec |
|
| [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections]. | 2001 Jan 10 |
|
| A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. | 2001 Jul |
|
| Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. | 2001 Jul |
|
| Inhibition of beta-lactamases by 6,6-bis(hydroxylmethyl)penicillanate. | 2001 Jun |
|
| Molecular epidemiology of antibiotic-resistant gram-negative bacilli in a neonatal intensive care unit during a nonoutbreak period. | 2001 Nov |
|
| The effect of a functional group in penicillin derivatives on the interaction with bile salt micelles studied by micellar electrokinetic chromatography. | 2001 Oct |
|
| A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. | 2001 Oct 15 |
|
| Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. | 2001 Sep |
|
| [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin]. | 2001 Sep |
|
| Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment. | 2001 Sep |
|
| [A multicenter clinical trial of piperacillin/tazobactam in burn infection]. | 2002 Apr |
|
| Synthesis of new C-6 alkyliden penicillin derivatives as beta-lactamase inhibitors. | 2002 Apr |
|
| Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. | 2002 Apr |
|
| Synthesis and biological evaluation of 6-bromo-6-substituted penicillanic acid derivatives as beta-lactamase inhibitors. | 2002 Aug |
|
| Selection of oxacillin resistance in oxacillin-sensitive Staphylococcus aureus through exposure to ciprofloxacin but not piperacillin/tazobactam. | 2002 Aug |
|
| Lemierre's disease caused by co-infection of Arcanobacterium haemolyticum and Fusobacterium necrophorum: a case report. | 2002 Aug |
|
| New and rapid fully automated method for determination of tazobactam and piperacillin in fatty tissue and serum by column-switching liquid chromatography. | 2002 Aug 5 |
|
| Postoperative infection with group A beta-hemolytic Streptococcus after blepharoplasty. | 2002 Dec |
|
| [Study on water of crystallization in tazobactam]. | 2002 Feb |
|
| Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue. | 2002 Feb |
|
| Comparison of aqueous and nonaqueous carrier electrolytes for the separation of penicillin V and related substances by capillary electrophoresis with UV and mass spectrometric detection. | 2002 Feb |
|
| Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. | 2002 Feb |
|
| Role of protein flexibility in enzymatic catalysis: quantum mechanical-molecular mechanical study of the deacylation reaction in class A beta-lactamases. | 2002 Feb 27 |
|
| Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. | 2002 Jan |
|
| Infecting one animal with two different strains of the same bacteria may cause misleading results. | 2002 Jul |
|
| Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. | 2002 Jul |
|
| Role of alphaArg145 and betaArg263 in the active site of penicillin acylase of Escherichia coli. | 2002 Jul 1 |
|
| Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry. | 2002 Jul 1 |
|
| Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. | 2002 Jun 1 |
|
| [Piperacillin-tazobactam in the treatment of severe nosocomial infections]. | 2002 Mar |
|
| High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 beta-lactamase. | 2002 Mar 20 |
|
| Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. | 2002 May |
|
| Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. | 2002 May |
|
| Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. | 2002 May |
|
| Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. | 2002 Nov |
|
| Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. | 2002 Nov |
|
| Factors governing intrinsic chemical reactivity differences between clavulanic and penicillanic acids. | 2002 Oct 9 |
|
| Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. | 2002 Sep |
|
| Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. | 2002 Sep |
|
| General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. | 2002 Sep 1 |
|
| Quantitative characterization of the nucleophile reactivity in penicillin acylase-catalyzed acyl transfer reactions. | 2002 Sep 23 |
|
| Mycotic aneurysm of the descending thoracic aorta caused by Pseudomonas aeruginosa in a solid organ transplant recipient: case report and review. | 2002 Spring |
|
| Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases. | 2003 Mar |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6891
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
DTXSID90236038
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
PIS09H0QIX
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
87-53-6
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
201-750-3
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
m8470
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
37806
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
